| HOME >> BIOLOGY >> TECHNOLOGY |
Innovative Custom Products, Inc., has obtained exclusive distribution rights to a 'first of its kind' product line, CureCeuticals, invented by Dr. Marc Selner, a nationally renowned Sports Podiatrist; Cure Toenail
Fungus and Cure Athlete's Foot.
MILWAUKEE, Nov. 7 /PRNewswire/ -- Joe Williams, President and Founder of Innovative Custom Products, Inc., announced today that his firm obtained exclusive distribution rights to a "first of its kind" product line, CureCeuticals, invented by Dr. Marc Selner, a nationally renowned Sports Podiatrist. The lead products in the CureCeuticals line are Cure Toenail Fungus and Cure Athlete's Foot. Both products are all-natural, all-organic, allopathic and homeopathic formulations. These cutting edge products are available without prescription and come in a convenient travel size. Williams said a full Skin Care line utilizing Dr. Selner's breakthrough "penetrating carrier technology" is in development and will be ready for distribution under the CureCeuticals brand within the next 12-18 months.
According to Dr. Selner, Cure Toenail Fungus is the only patent pending OTC topical that actually penetrates the nail, kills the fungus, and allows growth of a new, healthy nail. Cure Athlete's Foot unique formulation allows it to work on contact and eliminates most Athlete's Foot, Jock Itch, and Ringworm within 48 hours. Cure Athlete's Foot also relieves the itching, burning, and scaling associated with these conditions immediately upon application. These products have been used for years in doctors' offices to successfully treat and remedy toenail fungus (Onychomycosis) and athlete's foot (Tenia Pedis), respectively, without side effects.
Dr. Selner said that, unlike other products, Cure Toenail Fungus and
Cure Athlete's Foot utilize his "Penetrating Carrier Technology" to allow
the contained anti-fungal compounds to actually penetrate the nail or the
skin and go directly to where the fun
'/>"/>
| SOURCE Innovative Custom Products, Inc. Copyright©2007 PR Newswire. All rights reserved |